Valuation: Novavax, Inc.

Market Cap 1.75B 1.54B 1.45B 1.33B 2.48B 168B 2.5B 17.36B 6.73B 85.86B 6.58B 6.44B 276B P/E 2026 *
-17x
P/E 2027 * -47.4x
Enterprise Value 1.97B 1.73B 1.64B 1.49B 2.79B 189B 2.81B 19.53B 7.57B 96.59B 7.4B 7.24B 311B EV / Sales 2026 *
5.29x
EV / Sales 2027 * 7.73x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week+5.14%
Current month+13.45%
1 month+15.42%
3 months+19.71%
6 months+18.77%
Current year+58.18%
1 week 10.15
Extreme 10.15
11.09
1 month 8.89
Extreme 8.89
11.09
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
236.5
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
6/20/26 Exercice

Director

37,760 0.0230%
6/18/26 Free

Director

35,450 0.0216%
4/25/26 Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+5.14%+24.33%+49.51% 1.75B
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.11%+2.63%+58.41%+133.14% 27.18B
Weighted average by Cap. +0.11%+2.88%+79.29%+159.48%

Financials

2026 *2027 *
Net sales 373M 328M 309M 282M 528M 35.73B 532M 3.69B 1.43B 18.26B 1.4B 1.37B 58.79B 266M 234M 221M 201M 377M 25.5B 380M 2.64B 1.02B 13.03B 999M 978M 41.96B
Net income -108M -94.53M -89.23M -81.31M -152M -10.3B -153M -1.07B -413M -5.27B -404M -395M -16.95B -37.93M -33.34M -31.47M -28.68M -53.68M -3.63B -54.09M -376M -146M -1.86B -142M -139M -5.98B
Net Debt 219M 192M 182M 166M 310M 20.98B 312M 2.17B 840M 10.72B 822M 804M 34.52B 303M 267M 252M 229M 429M 29.05B 432M 3B 1.16B 14.85B 1.14B 1.11B 47.8B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-09-25 US$10.63 +0.28% 3,910,299
26-09-24 US$10.60 +0.47% 4,353,248
26-09-23 US$10.55 -2.59% 5,773,245
26-09-22 US$10.83 +4.03% 7,580,684
26-09-21 US$10.41 +2.97% 6,135,452
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.63USD
Average target price
14.00USD
Spread / Average Target
+31.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock